Actively Recruiting
Assessment of Geriatric Evaluations Impact on New AML Guidance
Led by Abramson Cancer Center at Penn Medicine · Updated on 2025-08-07
100
Participants Needed
1
Research Sites
161 weeks
Total Duration
On this page
Sponsors
A
Abramson Cancer Center at Penn Medicine
Lead Sponsor
B
Bristol-Myers Squibb
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.
CONDITIONS
Official Title
Assessment of Geriatric Evaluations Impact on New AML Guidance
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with AML by peripheral flow cytometry and/or bone marrow biopsy
- Newly diagnosed and considered for a new line of treatment
- Age 50 years or older
- Performance status of 0, 1, or 2
You will not qualify if you...
- Unable to understand or sign a written informed consent
- Unable to complete questionnaires independently and have no one to assist
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
C
Colleen Redlinger
CONTACT
C
Catherine Lai, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here